Development and validation of a nomogram based on stromal score to predict progression-free survival of patients with papillary thyroid carcinoma

被引:4
|
作者
Tang, Jiajia [1 ]
Jiang, Shitao [2 ]
Gao, Qiong [1 ]
Xi, Xuehua [3 ]
Gao, Luying [1 ]
Zhao, Ruina [1 ]
Lai, Xingjian [1 ]
Zhang, Bo [3 ]
Jiang, Yuxin [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Ultrasound, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Dept Med Ultrason, Beijing, Peoples R China
来源
CANCER MEDICINE | 2021年 / 10卷 / 16期
基金
中国国家自然科学基金;
关键词
nomogram; papillary thyroid carcinoma; progression-free survival; stromal score; STAGING SYSTEM; ASSOCIATION GUIDELINES; CANCER; WELL; AGE; IDENTIFICATION; CUTOFF;
D O I
10.1002/cam4.4112
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Growing evidence has proved that stromal cells, as the critical component of tumor microenvironment (TME), are closely associated with tumor's progression. However, the model based on stromal score to predict progression-free survival (PFS) in papillary thyroid carcinoma (PTC) has not been developed. The study aimed at exploring the relation between stromal score and prognosis, then establishing a nomogram to predict PFS of patients with PTC. Method We obtained the stromal score and clinicopathological characteristics of PTC patients from The Cancer Genome Atlas (TCGA) database. Cox regression analysis assisted in selecting prognosis-related factors. A stromal score-based nomogram was built and verified in the training and validation cohorts, respectively. The calibration curve, concordance index (C-index), decision curve analysis (DCA) as well as receiver operating characteristic (ROC) curve assisted in measuring the performance exhibited by the nomogram. Results We divided 381 PTC patients into the training cohort (n = 269) and the validation cohort (n = 112) randomly. Compared with patients who had a low stromal score, patients with a high stromal score appeared with significantly better PFS [Hazard ratio (HR) and 95% confidence interval (CI): 0.294, 0.130-0.664]. The C-index of the PFS nomogram was 0.764 (0.662-0.866) in the training cohort and 0.717 (0.603-0.831) in the validation cohort. The calibration curves for PFS prediction in the nomogram were remarkably consistent with the actual observation. DCA indicated superior performance of the nomogram to predict PFS than the American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM) staging system. The ROC curves showed the favorable sensitivity and specificity of the novel nomogram. Conclusion High stromal score was significantly associated with improved PFS in patients with PTC. The nomogram based on the stromal score and clinicopathological patterns yielded a reliable performance to predict the prognosis of PTC.
引用
收藏
页码:5488 / 5498
页数:11
相关论文
共 50 条
  • [1] Development of a nomogram to predict the progression-free survival in lung cancer patients
    Tafenzi, H. A.
    Choulli, F.
    Baladi, A.
    El Fadli, M.
    Essadi, I.
    Belbaraka, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S155 - S155
  • [2] Development of a nomogram to predict progression-free survival in patients with locally advanced renal cell carcinoma
    Xiao, Ruo-Tao
    Liu, Cheng
    Yang, Bin
    He, Wei
    Xu, Chu-Xiao
    Chen, Zhi-Gang
    Ma, Lu-Lin
    CHINESE MEDICAL JOURNAL, 2021, 134 (22) : 2765 - 2767
  • [3] Development of a nomogram to predict progression-free survival in patients with locally advanced renal cell carcinoma
    Ruo-Tao Xiao
    Cheng Liu
    Bin Yang
    Wei He
    Chu-Xiao Xu
    Zhi-Gang Chen
    Lu-Lin Ma
    中华医学杂志英文版, 2021, 134 (22) : 2765 - 2767
  • [4] Development and validation of a preoperative MRI-based radiomics nomogram to predict progression-free survival in patients with clival chordomas
    Zhai, Yixuan
    Bai, Jiwei
    Xue, Yake
    Li, Mingxuan
    Mao, Wenbin
    Zhang, Xuezhi
    Zhang, Yazhuo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Development and validation of a ferroptosis-related prognostic model for the prediction of progression-free survival and immune microenvironment in patients with papillary thyroid carcinoma
    Huang, Yinde
    Xie, Zhenyu
    Li, Xin
    Chen, Wenbin
    He, Yuzhen
    Wu, Song
    Li, Xinyang
    Hou, Bingchen
    Sun, Jianjian
    Wang, Shiyue
    He, Yuchen
    Jiang, Han
    Lun, Yu
    Zhang, Jian
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101
  • [6] Development and validation of a prognostic nomogram for progression-free survival in patients with advanced renal cell carcinoma treated with pazopanib
    Kattan, Michael W.
    Sternberg, Cora N.
    Mehmud, Faisal
    Bhatt, Kamal
    McCann, Lauren
    Motzer, Robert J.
    ONKOUROLOGIYA, 2015, 11 (04): : 16 - 23
  • [7] Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib
    Kattan, Michael W.
    Sternberg, Cora N.
    Mehmud, Faisal
    Bhatt, Kamal
    McCann, Lauren
    Motzer, Robert J.
    ONCOLOGY, 2015, 89 (04) : 235 - 241
  • [8] A nomogram to predict the progression-free survival of clival chordoma
    Zhai, Yixuan
    Bai, Jiwei
    Li, Mingxuan
    Wang, Shuai
    Li, Chuzhong
    Wei, Xinting
    Zhang, Yazhuo
    JOURNAL OF NEUROSURGERY, 2021, 134 (01) : 144 - 152
  • [9] Development and validation of a nomogram to predict cancer-specific survival in elderly patients with papillary thyroid carcinoma: a population-based study
    Wang, Jinkui
    Zhanghuang, Chenghao
    Jin, Liming
    Zhang, Zhaoxia
    Tan, Xiaojun
    Mi, Tao
    Liu, Jiayan
    Li, Mujie
    Wu, Xin
    Tian, Xiaomao
    He, Dawei
    BMC GERIATRICS, 2022, 22 (01)
  • [10] Development and validation of a nomogram to predict cancer-specific survival in elderly patients with papillary thyroid carcinoma: a population-based study
    Jinkui Wang
    Chenghao Zhanghuang
    Liming Jin
    Zhaoxia Zhang
    Xiaojun Tan
    Tao Mi
    Jiayan Liu
    Mujie Li
    Xin Wu
    Xiaomao Tian
    Dawei He
    BMC Geriatrics, 22